US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

41.85

-0.5680-1.34%

Volume:244

Turnover:10.16K

Market Cap:29.30M

PE:- -

High:41.85

Open:42.42

Low:41.85

Close:42.42

52wk High:45.58

52wk Low:31.44

Shares:700.00K

Float Shares:700.00K

Volume Ratio:0.04

T/O Rate:0.03%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Ligand Pharmaceuticals Incorporated - Commits up to $6 Mln in Series C Financing

THOMSON REUTERS

Press Release: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million

Editas slips amid pressure on gene-editing sector after Anthropic update

Ligand Pharmaceuticals Incorporated : Citigroup Raises Target Price to $397 from $390

THOMSON REUTERS

Ligand price target raised to $397 from $390 at Citi

Natera Inc Stock (NTRA) Moved Up by 5.67% on Sep 22: Facts Behind the Movement

New precision medicine venture gives Syngenis added firepower

The West Australian

Ligand Pharmaceuticals Joins Signet-Led Financing Round in Primrose Bio

Sydnexis : Agreement Includes $23 Mln Upfront Payment

THOMSON REUTERS

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea

THOMSON REUTERS

Press Release: Primrose Bio(R) Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Natera’s Signatera Wins Japan PMDA Approval as Companion Diagnostic in Muscle-Invasive Bladder Cancer

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

THOMSON REUTERS

Natera- Signatera Commercial Launch in Japan Expected in 1H 2027

THOMSON REUTERS

Ligand Buys Ryjunea Royalty, Milestone Interest from Sydnexis for $23 Million

Ligand Pharmaceuticals Incorporated - to Receive Tiered Royalty on Ryjunea Net Sales in Emea

THOMSON REUTERS

Ligand Pharmaceuticals Incorporated - Buys Rights to Royalty and Milestone Payments on Ryjunea in Emea

THOMSON REUTERS

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

THOMSON REUTERS

Adaptive Biotechnologies Price Target Raised to $34.00/Share from $25.00 by BTIG

Analysts Are Bullish on These Healthcare Stocks: Ligand Pharma (LGND), Disc Medicine (IRON)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/HELX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":41.8522,"timestamp":1791489600000,"preClose":42.4202,"halted":0,"volume":244,"delay":0,"changeRate":-0.013389847289734556,"floatShares":700000,"shares":700000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.568,"latestTime":"10-09 04:37:32 EDT","open":42.4202,"high":41.8522,"low":41.8522,"amount":10157,"amplitude":0,"askPrice":66.54,"askSize":100,"bidPrice":16.83,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"exchange":"CBOE","adjPreClose":41.8522,"sharesOutstanding":650000,"nav":42.394,"aum":29675530.04,"dividendRate":0.003445,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.4202,"preClose":41.8522,"latestTime":"16:10 EDT","volume":7,"amount":292.9654,"timestamp":1791490204748,"change":0.568,"changeRate":0.013572,"amplitude":0},"volumeRatio":0.03608506551963128,"impliedVol":0.1194,"impliedVolPercentile":0.42},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.03608506551963128,"shares":700000,"dividePrice":0.1442,"high":41.8522,"amplitude":0,"preClose":42.4202,"low":41.8522,"week52Low":31.44,"pbRate":"--","week52High":45.58,"institutionHeld":0,"latestPrice":41.8522,"eps":0,"divideRate":0.003445,"volume":244,"delay":0,"ttmEps":0,"open":42.4202,"prevYearClose":36.3062,"prevWeekClose":43.79,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":43.53,"twentyDayClose":41.0314,"sixtyDayClose":39.7145},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669462584","title":"Ligand Pharmaceuticals Incorporated - Commits up to $6 Mln in Series C Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2669462584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669462584?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA7SZPQL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","HELX","LGND","IE0009354923.USD","LU0566484027.USD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669462637","title":"Press Release: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669462637","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669462637?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":"JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4099","BK4232","LU1559883803.SGD","BK4585","BK4588","BK4007","R","TM","CAR","LU0566484027.USD","BK4022","03160","LENZ","LGND","BK4539","BK4555","HELX","BK4139","BK4604","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669435367","title":"Editas slips amid pressure on gene-editing sector after Anthropic update","url":"https://stock-news.laohu8.com/highlight/detail?id=2669435367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669435367?lang=en_us&edition=fundamental","pubTime":"2026-09-24 02:55","pubTimestamp":1790189712,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) is trading lower alongside other gene editing peers after Anthropic shared early findings on a CRISPR like enzyme system. An...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-slips-amid-pressure-on-gene-editing-sector-after-anthropic-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-slips-amid-pressure-on-gene-editing-sector-after-anthropic-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","CRSP","HELX","BK4585","BK4588","IDNA","LU1861559042.SGD","ARKG","BK4556","BK4611","EDIT","SYNB","WDNA","BK4139","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669558102","title":"Ligand Pharmaceuticals Incorporated : Citigroup Raises Target Price to $397 from $390","url":"https://stock-news.laohu8.com/highlight/detail?id=2669558102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669558102?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:50","pubTimestamp":1790157016,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0CR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","HELX","LGND","BK4139","IE0009354923.USD","BK4007","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669024781","title":"Ligand price target raised to $397 from $390 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2669024781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669024781?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:45","pubTimestamp":1790156708,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Ligand (LGND) to $397 from $390 and keeps a Buy rating on the shares. The firm cites the company’s acquisiti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ligand-price-target-raised-to-397-from-390-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ligand-price-target-raised-to-397-from-390-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","BK4007","HELX","LGND","LU1559883803.SGD","BK4139","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669861121","title":"Natera Inc Stock (NTRA) Moved Up by 5.67% on Sep 22: Facts Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669861121","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669861121?lang=en_us&edition=fundamental","pubTime":"2026-09-23 02:15","pubTimestamp":1790100924,"startTime":"0","endTime":"0","summary":"• Natera's clinical milestones and Signatera validation bolstered investor confidence.\n• Management highlighted accelerating test adoption and long-term gross margin expansion.\n• Wall Street sentiment remains favorable with multiple analysts issuing buy ratings.","market":"hk","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262181061-market-movers-ntra-20260922","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU1064131342.USD","LU2065171402.SGD","LU0963586101.USD","LU0012050646.USD","NTRA","LU2065170008.USD","LU0106261612.USD","HELX","GNOM","LU0345770993.USD","LU2065171311.SGD","LU1988902786.USD","LU2324357040.USD","BK4139","LU2065169927.USD","LU0345770308.USD","LU2065731478.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669175122","title":"New precision medicine venture gives Syngenis added firepower","url":"https://stock-news.laohu8.com/highlight/detail?id=2669175122","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669175122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:27","pubTimestamp":1790094446,"startTime":"0","endTime":"0","summary":"Syngenis has joined the renowned Perron Institute and Gene S founders in a precision-medicine venture that puts its integrated DNA and RNA platform to work and opens the door to recurring manufacturing revenue.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["SLF.AU","BEAR.AU","OZR.AU","STW.AU","ZYAU.AU","XAO.AU","OZF.AU","GIVE.AU","QFN.AU","GDOC","IIGF.AU","TMAT","FDIF","WDNA","BMED","IDNA","GNMX","VAS.AU","IOZ.AU","LFSC","XKO.AU","HELX","SYNB","GEAR.AU","IMLC.AU","VAP.AU","HTEC","E200.AU","BBOZ.AU","IBB","QRE.AU","MEDX","BK4585","EIGA.AU","ADHD","JDOC","BK4588","DACE.AU","GNOM","IISV.AU","XT","XJO.AU","PBE","EES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142256","title":"Ligand Pharmaceuticals Joins Signet-Led Financing Round in Primrose Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142256","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142256?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:04","pubTimestamp":1790082279,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals joins Signet-led financing round in Primrose BioPrimrose Bio closed a financing round led by new investor Signet Healthcare Partners, with participation from Ligand Pharmaceutic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL3qpSgQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGND","LU1559883803.SGD","BK4007","IE0009354923.USD","LU0566484027.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669314243","title":"Sydnexis : Agreement Includes $23 Mln Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2669314243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669314243?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0DF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009354923.USD","BK4139","BK4007","HELX","LU0566484027.USD","LU1559883803.SGD","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142436","title":"Sydnexis Announces Royalty Agreement with Ligand for Ryjunea","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142436","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142436?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082140,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HELX","BK4139","LGND","LU1559883803.SGD","IE0009354923.USD","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669421791","title":"Press Release: Primrose Bio(R) Raises Significant Growth Capital Investment Led by Signet Healthcare Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2669421791","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669421791?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. , a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners , with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated , LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose's Board of Directors.The proceeds will help Primrose continue to expand the reach and capabilities of its differentiated technology portfolio:-- Pfenex Expression Technology , a scalable microbial. expression platform for efficient, high-yield production of complex,-- Prima RNApols, proprietary RNA polymerases for consistent, scalable,-- PeliCRM197, a validated carrier protein used in multiple approved","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","LGND","BK4581","XBI","BK4232","BK4137","LU0029874061.USD","LU1559883803.SGD","IE0009354923.USD","XLV","R","BK4022","LU0566484027.USD","LU0128526141.USD","BK4007","BK4139","LABU","BK4585","BK4588","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414421","title":"Natera’s Signatera Wins Japan PMDA Approval as Companion Diagnostic in Muscle-Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414421","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414421?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:04","pubTimestamp":1790078642,"startTime":"0","endTime":"0","summary":"Natera’s Signatera wins Japan PMDA approval as companion diagnostic in muscle-invasive bladder cancerNatera won PMDA clearance in Japan for Signatera as a companion diagnostic in muscle-invasive bladd","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL8Klqhw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","LU0963586101.USD","LU1988902786.USD","GNOM","LU0106261612.USD","LU2324357040.USD","LU2065731478.USD","BK4139","LU0012050646.USD","LU2065170008.USD","LU0053671581.USD","LU0345770308.USD","LU1064131342.USD","LU2065169927.USD","LU2065171402.SGD","NTRA","LU0345770993.USD","HELX","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669600141","title":"Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669600141","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669600141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA93GLLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1988902786.USD","LU2264538146.SGD","GNOM","LU2065169927.USD","LU0345770993.USD","LU0345770308.USD","LU2065171311.SGD","LU2065171402.SGD","LU2324357040.USD","NTRA","LU1064131342.USD","LU0053671581.USD","LU0012050646.USD","HELX","LU0106261612.USD","BK4139","LU2065170008.USD","LU2065731478.USD","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141228","title":"Natera- Signatera Commercial Launch in Japan Expected in 1H 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141228?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA93GLLM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GNOM","LU0106261612.USD","LU0345770308.USD","NTRA","LU0053671581.USD","LU0012050646.USD","LU1988902786.USD","HELX","LU0345770993.USD","LU0963586101.USD","LU1064131342.USD","BK4139","LU2324357040.USD","LU2065731478.USD","LU2065171402.SGD","LU2065171311.SGD","LU2065170008.USD","LU2065169927.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146936","title":"Ligand Buys Ryjunea Royalty, Milestone Interest from Sydnexis for $23 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146936","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146936?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:02","pubTimestamp":1790074938,"startTime":"0","endTime":"0","summary":"Ligand buys Ryjunea royalty, milestone interest from Sydnexis for $23 millionLigand Pharmaceuticals bought a 100% interest in Sydnexis payment rights tied to Santen’s Ryjunea for a USD 23 million upfr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL5zH3n5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LGND","LU2210149790.SGD","IE00BGHQF748.EUR","BK4007","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BN0W2V16.EUR","IE00BQXX3C00.GBP","LU0566484027.USD","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ","LU0314104364.USD","BK4112","BK4585","LU1559883803.SGD","IE00BKPKM429.USD","BCDF","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","SG9999014039.USD","BK4139","IE0009354923.USD","IE00B64PRP62.GBP","SG9999014005.SGD","BK4588","HELX","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669814659","title":"Ligand Pharmaceuticals Incorporated - to Receive Tiered Royalty on Ryjunea Net Sales in Emea","url":"https://stock-news.laohu8.com/highlight/detail?id=2669814659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669814659?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:00","pubTimestamp":1790074801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABLLRPD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IE0009354923.USD","HELX","LU0566484027.USD","LU1559883803.SGD","BK4139","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146592","title":"Ligand Pharmaceuticals Incorporated - Buys Rights to Royalty and Milestone Payments on Ryjunea in Emea","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146592","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146592?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:00","pubTimestamp":1790074801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABLLRPD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","LU1559883803.SGD","LU0566484027.USD","HELX","LGND","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146516","title":"Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146516?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:00","pubTimestamp":1790074801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABLLRPD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGND","LU1559883803.SGD","BK4007","IE0009354923.USD","BK4139","HELX","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437251","title":"Adaptive Biotechnologies Price Target Raised to $34.00/Share from $25.00 by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437251","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437251?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:19","pubTimestamp":1790072340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669148615","title":"Analysts Are Bullish on These Healthcare Stocks: Ligand Pharma (LGND), Disc Medicine (IRON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669148615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669148615?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:30","pubTimestamp":1790069407,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGND), Disc Medicine (IRON) and Immun...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-ligand-pharma-lgnd-disc-medicine-iron-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-ligand-pharma-lgnd-disc-medicine-iron-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRON","XLV","LU0053671581.USD","LGND","BK4588","LABU","LU0566484027.USD","LU0128526141.USD","XBI","BK4585","BK4137","HELX","LU0029874061.USD","IE0009354923.USD","HCSG","BK4007","LU1559883803.SGD","BK4139","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}